Literature DB >> 23069657

DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats.

H-X Yan1, H-P Wu, H-L Zhang, C Ashton, C Tong, J Wu, Q-J Qian, H-Y Wang, Q-L Ying.   

Abstract

The tumor suppressor p53 has an important role in inducing cell-intrinsic responses to DNA damage, including cellular senescence or apoptosis, which act to thwart tumor development. It has been shown, however, that senescent or dying cells are capable of eliciting inflammatory responses, which can have pro-tumorigenic effects. Whether DNA damage-induced p53 activity can contribute to senescence- or apoptosis-associated pro-tumorigenic inflammation is unknown. Recently, we generated a p53 knock-out rat via homologous recombination in rat embryonic stem cells. Here we show that in a rat model of inflammation-associated hepatocarcinogenesis, heterozygous deficiency of p53 resulted in attenuated inflammatory responses and ameliorated hepatic cirrhosis and tumorigenesis. Chronic administration of hepatocarcinogenic compound, diethylnitrosamine, led to persistent DNA damage and sustained induction of p53 protein in the wild-type livers, and much less induction in p53 heterozygous livers. Sustained p53 activation subsequent to DNA damage was accompanied by apoptotic rather than senescent hepatic injury, which gave rise to the hepatic inflammatory responses. In contrast, the non-hepatocarcinogenic agent, carbon tetrachloride, failed to induce p53, and caused a similar degree of chronic hepatic inflammation and cirrhosis in wild type and p53 heterozygous rats. These results suggest that although p53 is usually regarded as a tumor suppressor, its constant activation can promote pro-tumorigenic inflammation, especially in livers exposed to agents that inflict lasting mutagenic DNA damage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069657      PMCID: PMC3855850          DOI: 10.1038/onc.2012.451

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson; Joe W Grisham
Journal:  Nat Genet       Date:  2002-08       Impact factor: 38.330

2.  Laboratory animals: the Renaissance rat.

Authors:  Alison Abbott
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

3.  Integrity of p53 in hepatitis B x antigen-positive and -negative hepatocellular carcinomas.

Authors:  M S Greenblatt; M A Feitelson; M Zhu; W P Bennett; J A Welsh; R Jones; A Borkowski; C C Harris
Journal:  Cancer Res       Date:  1997-02-01       Impact factor: 12.701

Review 4.  Tumor promotion via injury- and death-induced inflammation.

Authors:  Ali Kuraishy; Michael Karin; Sergei I Grivennikov
Journal:  Immunity       Date:  2011-10-28       Impact factor: 31.745

5.  Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice.

Authors:  Takahiro Kodama; Tetsuo Takehara; Hayato Hikita; Satoshi Shimizu; Minoru Shigekawa; Hinako Tsunematsu; Wei Li; Takuya Miyagi; Atsushi Hosui; Tomohide Tatsumi; Hisashi Ishida; Tatsuya Kanto; Naoki Hiramatsu; Satoshi Kubota; Masaharu Takigawa; Yoshito Tomimaru; Akira Tomokuni; Hiroaki Nagano; Yuichiro Doki; Masaki Mori; Norio Hayashi
Journal:  J Clin Invest       Date:  2011-07-11       Impact factor: 14.808

Review 6.  N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation.

Authors:  L Verna; J Whysner; G M Williams
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

7.  Hepatocarcinogenesis in p53-deficient mice.

Authors:  C J Kemp
Journal:  Mol Carcinog       Date:  1995-03       Impact factor: 4.784

8.  Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.

Authors:  C J Kemp; L A Donehower; A Bradley; A Balmain
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

9.  p53 expression in patients with cirrhosis with and without hepatocellular carcinoma.

Authors:  N Livni; A Eid; Y Ilan; A Rivkind; E Rosenmann; L M Blendis; D Shouval; E Galun
Journal:  Cancer       Date:  1995-05-15       Impact factor: 6.860

10.  Liver carcinogenesis by diethylnitrosamine in the rat.

Authors:  M F Rajewsky; W Dauber; H Frankenberg
Journal:  Science       Date:  1966-04-01       Impact factor: 47.728

View more
  10 in total

1.  p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release.

Authors:  He-Xin Yan; Hong-Ping Wu; Hui-Lu Zhang; Charles Ashton; Chang Tong; Han Wu; Qi-Jun Qian; Hong-Yang Wang; Qi-Long Ying
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

2.  Absence of a p53 allele delays nitrogen mustard-induced early apoptosis and inflammation of murine skin.

Authors:  Swetha Inturi; Neera Tewari-Singh; Anil K Jain; Srirupa Roy; Carl W White; Rajesh Agarwal
Journal:  Toxicology       Date:  2013-07-08       Impact factor: 4.221

3.  The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation.

Authors:  C-C Chen; K-H Kim; L F Lau
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

4.  Diethylnitrosamine Increases Proliferation in Early Stages of Hepatic Carcinogenesis in Insulin-Treated Type 1 Diabetic Mice.

Authors:  A S Arboatti; F Lambertucci; M G Sedlmeier; G Pisani; J Monti; M de L Álvarez; D E A Francés; M T Ronco; C E Carnovale
Journal:  Biomed Res Int       Date:  2018-04-23       Impact factor: 3.411

5.  EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.

Authors:  Alexander Ring; Pushpinder Kaur; Julie E Lang
Journal:  BMC Cancer       Date:  2020-11-10       Impact factor: 4.430

Review 6.  The landscape of aging.

Authors:  Yusheng Cai; Wei Song; Jiaming Li; Ying Jing; Chuqian Liang; Liyuan Zhang; Xia Zhang; Wenhui Zhang; Beibei Liu; Yongpan An; Jingyi Li; Baixue Tang; Siyu Pei; Xueying Wu; Yuxuan Liu; Cheng-Le Zhuang; Yilin Ying; Xuefeng Dou; Yu Chen; Fu-Hui Xiao; Dingfeng Li; Ruici Yang; Ya Zhao; Yang Wang; Lihui Wang; Yujing Li; Shuai Ma; Si Wang; Xiaoyuan Song; Jie Ren; Liang Zhang; Jun Wang; Weiqi Zhang; Zhengwei Xie; Jing Qu; Jianwei Wang; Yichuan Xiao; Ye Tian; Gelin Wang; Ping Hu; Jing Ye; Yu Sun; Zhiyong Mao; Qing-Peng Kong; Qiang Liu; Weiguo Zou; Xiao-Li Tian; Zhi-Xiong Xiao; Yong Liu; Jun-Ping Liu; Moshi Song; Jing-Dong J Han; Guang-Hui Liu
Journal:  Sci China Life Sci       Date:  2022-09-02       Impact factor: 10.372

Review 7.  Current and emerging biomarkers of cell death in human disease.

Authors:  Kongning Li; Deng Wu; Xi Chen; Ting Zhang; Lu Zhang; Ying Yi; Zhengqiang Miao; Nana Jin; Xiaoman Bi; Hongwei Wang; Jianzhen Xu; Dong Wang
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

8.  p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways.

Authors:  Maria Shatz; Igor Shats; Daniel Menendez; Michael A Resnick
Journal:  Oncotarget       Date:  2015-07-10

Review 9.  p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine.

Authors:  Jelena Krstic; Markus Galhuber; Tim J Schulz; Michael Schupp; Andreas Prokesch
Journal:  Int J Mol Sci       Date:  2018-03-20       Impact factor: 6.208

10.  In Vitro Evaluation of the Cytotoxic Effect of Streptococcus pyogenes Strains, Protegrin PG-1, Cathelicidin LL-37, Nerve Growth Factor and Chemotherapy on the C6 Glioma Cell Line.

Authors:  Alexandr N Chernov; Anna Tsapieva; Diana A Alaverdian; Tatiana A Filatenkova; Elvira S Galimova; Mariia Suvorova; Olga V Shamova; Alexander N Suvorov
Journal:  Molecules       Date:  2022-01-17       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.